Abstract:Background Hypertension is one of the most urgent public health challenges, and drug therapy is the primary method to control blood pressure for patients. However, blood pressure control rate is still poor with antihypertensive drugs use. Although Clinical Prediction Rules (CPR) is useful to help clinicians make more appropriate decisions at the point of medication, the evidence is still limited in china. The objective of this study is to develop an CPR of antihypertensive drugs in individualized application of patients based on real-world practice. Methods A two-way cohort study has been conducted in one China’s large tertiary hospital using clinical information on patient characteristics, drug use and clinical outcome. Data extraction is through ICD-10 disease codes of hypertension from Electronic Medical Record System. Eligible patients admitted from September 2016 to August 2018 who have received at least one antihypertensive drug therapy is included. Patients were grouped into several exposure groups according to medications. COX regression model and clinical specialty survey is applied to identify Influencing Factors (IF) in different study groups, and the discriminant model was used to construct a CPR according IF. The accuracy of the CPR is analyzed by sensitivity, specificity, Youden’s index and Receiver Operating Characteristic (ROC) curve. Discussion Result is expected to provide valuable CPR for physicians and policymakers with respect to treating hypertension according characteristic of individual patients. By developing a predictive method for clinical outcomes and treatment costs of antihypertensive medication, we expect to discriminate those patients who would profit from specific scheme of antihypertensive drugs to minimal incidence probability of costs and complications in region of china. Trial registration This study was registered at [www.chictr.org][1] as a primary register of the WHO International Clinical Trials Registry Platform (ICTRP), and the registered number is ChiCTR1900026339. Highlights Although Clinical Prediction Rules (CPR) could recognize individual patient risk and help clinicians to make more appropriate decision at the point of medication as part of clinical decision support systems, the evidence in this respect is still limited in China. This study is first going to construct the CPR of multiple antihypertensive drugs in real world practice of China. The highlights of this study is aimed to provide a pragmatic method to support clinical decisions for patients who has received antihypertensive drugs before long-term diagnosis of hypertension in real world practice according to their characteristics that are accessible to clinicians. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial ChiCTR1900026339 ### Funding Statement Not applicable. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The datasets used and/or analysis during the current study are available from the corresponding author on reasonable request. * CPR : Clinical Prediction Rules CDSS : Clinical Decision Support Systems AHD : Antihypertensive drugs (AHD) AI : Artificial intelligence IF : Influencing Factors EMRC : Electronic Medical Record System DALY : Disability-Adjusted Life Year [1]: http://www.chictr.org

Real-world research on beta-blocker usage trends in China and safety exploration based on the FDA Adverse Event Reporting System (FAERS)

Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study.

Developing an Individualized Clinical Prediction Rules of Antihypertensive Drugs: A Study Protocol Based on Real-world Practice

10-year Trend of Early Beta Receptor Blocker Application for Acute Myocardial Infarction Patients in Western Rural China

Prevalence and Risk of Atrial Fibrillation in China: A National Cross-Sectional Epidemiological Study

Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study

Expert Panel of the Chinese Society of Cardiology Recommendations on Beta-Blocker Therapy in Patients Undergoing Non-Cardiac Surgery

An Investigation of Pharmacovigilance and Reporting of Adverse Drug Reactions in Hospitals: a Cross-Sectional Study in China

Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS

Current Status of Antiarrhythmic Drug Use and Safety Assessment in Chinese Patients with Atrial Fibrillation

[Current status and influence factors of beta blocker prescription in Chinese patients with stable angina pectoris].

Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone

Early β-blocker use and in-hospital outcomes in patients with chronic obstructive pulmonary disease hospitalized with acute coronary syndrome: findings from the CCC-ACS project

β-blockades and the risk of atrial fibrillation in patients with cardiovascular diseases

Safety assessment of Yasmin: Real-world adverse event analysis using the FAERS database

Use of Drug Treatment for Secondary Prevention of Cardiovascular Disease in Urban and Rural Communities of China: China Kadoorie Biobank Study of 0.5 Million People

A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen

A3704 CHINA STudy of Valsartan/amlodipine Fixed-Dose Combination-Based Long-Term Blood Pressure Management in HypertenSive Patients

Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.

Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database

New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China